UNC alum, pharmaceutical exec Fred Eshelman makes another investment: experimental cancer treatment
Posted Apr 28, 2015
Fred Eshelman made another move by joining a group that invested $28 million in Innocrin Pharmaceuticals, a company developing treatments for breast and prostate cancers. Eshelman, who recently founded Eshelman Ventures, also joined Innocrin's board.
(Triangle Business Journal)
Related: Campus Connections
Chapel Hill's Siena Hotel Leadership Recaps Busy Week Hosting Mexico Men’s National TeamThe Mexico men’s soccer national team earned a 1-0 win over Türkiye on Tuesday at Kenan Stadium, part of the team’s ongoing MEXTOUR ahead of...
Tue Jun 17, 2025Video: The Carolina Roots of Shibumi Shades
Meet the University of North Carolina alumni who created the Shibumi Shade, a popular wind-powered beach canopy that's now a fixture on about 800 beaches...
Mon Jun 16, 2025
Look back at the Class of 2025’s 4 years at Carolina
As the University of North Carolina Clef Hangers serenaded Tar Heel graduates near the end of Spring Commencement with a rendition of James Taylor’s “Carolina...
Sun Jun 15, 2025
'Power of theater': UNC Department of Dramatic Art receives $2 million gift from alumna
University of North Carolina alumna Kathleen Ford has given a $2 million gift to the Department of Dramatic Art. The gift consists of a $1...
Fri Jun 13, 2025